Benzinga | Aug 13, 2021 05:10AM EDT

Morgan Stanley Downgrades Aprea Therapeutics to Underweight, Lowers Price Target to $3

Morgan Stanley analyst Jeffrey Hung downgrades Aprea Therapeutics (NASDAQ:APRE) from Equal-Weight to Underweight and lowers the price target from $5 to $3.